By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC Over the course of my career in healthcare, I’ve been fortunate to serve in a leadership role through four IPOs and even more

By Philip Astley-Sparke, CEO of Replimune, as part of the From The Trenches feature of LifeSciVC. One of the biggest elephants in the room regarding starting and scaling young companies is the tension, often healthy but sometimes detrimental, that exist

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC Prioritization is a concept that we have become intimately aware of, given the continually blurred lines of personal and professional obligations in a

Biotech punches way above its weight-class, and that’s never been more apparent than in this pandemic and the race for a COVID vaccine. For those of us in biopharma, it feels like it’s a large and dynamic sector populated by

Part 2: Gaining leverage – and using it wisely By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC. In a recent blog post, I walked through my tips for reading your adversaries’

Part 1: Maintaining your cool – while making your adversary sweat By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC It’s back-to-school season, and that puts me in the frame of

By Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC I have many fond memories of St Patrick’s Day—most of them involve marching in the parade with a plastic bag and a few

SPACs are all the rage today. With the IPO market booming and public investors seeking better returns, blank check companies called “Special Purpose Acquisition Companies” (SPACs) have been fueling up their tanks and chasing down their merger targets. New ones

By Joachim Boekelmann and Joshua Brumm, as part of the From The Trenches feature of LifeSciVC.   At first blush, we may seem an unlikely duo: An attorney for a global insurance company living with a rare form of muscular dystrophy

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Earlier this fall, we prepared to report Phase III data for tebipenem HBr, our oral medication that, if approved, could help 2.7M patients

In the excitement of today’s biotech IPO market, and the bullish period since 2013, it’s almost hard to remember how painful the equity capital markets were back in the day. When I began my career in venture capital in 2004,

By Pamela L. Esposito, CBO of Replimune, as part of the From The Trenches feature of LifeSciVC. “You gotta know when to hold ‘em, know when to fold ‘em, know when to walk away, know when to run…” Kenny Rogers’